Holen Sie sich die Stockscreener-App
0.972
0.83%
0.0105
Schlusskurs vom Vortag:
$0.9615
Offen:
$0.97
24-Stunden-Volumen:
460.74K
Relative Volume:
0.37
Marktkapitalisierung:
$104.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.30M
KGV:
-3.4591
EPS:
-0.281
Netto-Cashflow:
$-18.79M
1W Leistung:
-8.54%
1M Leistung:
-8.54%
6M Leistung:
-24.26%
1J Leistung:
+55.62%
1-Tages-Spanne:
$0.955
$0.9885
1-Wochen-Bereich:
$0.9492
$1.09
52-Wochen-Spanne:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9695 | 103.46M | 0 | -25.30M | -18.79M | -0.281 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.87 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.20 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.39 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock - MarketBeat
Insider Buying: James Parsons Acquires Additional Shares of Oncolytics Biotech Inc (ONCY) - GuruFocus
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
What is Oncolytics Biotech Incs 5 year growth outlookProduct Launch & Verified Swing Trading Watchlists - baoquankhu1.vn
How Oncolytics Biotech Inc. stock compares to market leadersProfit Target & Step-by-Step Swing Trade Plans - Naître et grandir
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types - marketscreener.com
Oncolytics Biotech Advances Pelareorep Into New Phase 2 Colorectal Cancer Study - TipRanks
Cancer Treatment Breakthroughs Stack Up as Clinical Pipelines Advance - Baystreet.ca
Earnings Report: Is Oncolytics Biotech Inc undervalued by DCF analysisJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion - Cantech Letter
Oncolytics Biotech Launches Randomized Phase 2 REO-033 Trial for Pelareorep in RAS-Mutant MSS Metastatic Colorectal Cancer — With FDA Fast Track Behind It - Oncodaily
Oncolytics launches phase 2 colorectal cancer study REO 033 By Investing.com - Investing.com Canada
Oncolytics launches phase 2 colorectal cancer study REO 033 - Investing.com
Oncolytics Biotech Launches Phase 2 Colorectal Cancer Trial - TipRanks
Oncolytics Biotech Launches Randomized Colorectal Cancer Study - Bitget
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (NASDAQ: ONCY) launches Phase 2 pelareorep colorectal cancer study - Stock Titan
Oncolytics Biotech Inc initiates phase 2 study for metastatic colorectal cancer - marketscreener.com
Oncolytics (ONCY) Initiates Phase 2 Trial for Metastatic Colorec - GuruFocus
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - The Manila Times
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Enrollment Milestone - simplywall.st
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Milestone - Sahm
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday - MarketBeat
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY) - The Globe and Mail
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude - MSN
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 - Cantech Letter
Oncolytics to wind down GOBLET study, focus on U.S. registration - Investing.com India
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - The Malaysian Reserve
Death Cross: Will Oncolytics Biotech Inc outperform the market in YEARJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Foc - GuruFocus
Oncolytics to wind down GOBLET study, focus on U.S. registration By Investing.com - Investing.com Canada
Oncolytics to stop enrollments for GIT cancer trial (ONCY) - Seeking Alpha
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncolytics (ONCY) Completes Enrollment in GOBLET Study, Advances Cancer Research - GuruFocus
Cancer Drug Market on Track to Double by 2033: Five Oncology Plays to Watch - Baystreet.ca
Oncolytics Refocuses Pipeline on Key GI Cancer Programs - TipRanks
Oncolytics Biotech (ONCY) pivots to registration-focused anal and colorectal cancer trials - Stock Titan
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer - GlobeNewswire
Can Oncolytics Biotech Inc expand its profit marginsQuarterly Profit Summary & Growth Focused Stock Reports - baoquankhu1.vn
Trading Recap: How sensitive is Oncolytics Biotech Inc to inflationWeekly Loss Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Risk Off: Is Oncolytics Biotech Inc undervalued by DCF analysis2025 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
What are Oncolytics Biotech Inc.’s earnings expectationsPortfolio Performance Summary & Low Risk High Reward Ideas - mfd.ru
Patterns Watch: How is Oncolytics Biotech Inc managing supply chain issuesJuly 2025 PreEarnings & Community Consensus Trade Signals - baoquankhu1.vn
Aug Spikes: Can Oncolytics Biotech Inc expand its profit marginsMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Big Money Moves: What drives CRWDs stock price2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
THE INFRASTRUCTURE REALIGNMENT: 5 Stocks Positioning for the 2026 Supply Imperative - The Globe and Mail
Smart Money: What is Oncolytics Biotech Incs 5 year growth outlookMarket Movers & Community Verified Trade Signals - baoquankhu1.vn
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oncolytics Biotech Inc-Aktie (ONCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
| Aromando Andrew | Chief Business Officer |
Feb 11 '26 |
Buy |
0.86 |
29,600 |
25,418 |
55,100 |
| Andrews Patricia S | Director |
Feb 12 '26 |
Buy |
0.86 |
35,400 |
30,292 |
78,128 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):